Page last updated: 2024-12-06

5-bromocytosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

5-bromocytosine is a synthetic nucleoside analog that has been extensively studied for its potential applications in medicine and biotechnology. It is a potent inhibitor of DNA polymerase and can be used as a chemotherapeutic agent for the treatment of cancer. Additionally, 5-bromocytosine can be incorporated into DNA sequences and used as a probe in various molecular biology techniques. Its high density of bromine atoms allows for efficient detection and analysis. The synthesis of 5-bromocytosine typically involves a reaction between cytidine and bromine in the presence of a suitable catalyst, such as iodine. 5-bromocytosine has also been investigated for its potential role in epigenetic regulation, where it can modify DNA methylation patterns and affect gene expression. '

Cross-References

ID SourceID
PubMed CID75233
CHEMBL ID184965
SCHEMBL ID64109
MeSH IDM0269864

Synonyms (53)

Synonym
4-amino-5-bromopyrimidin-2-ol
4-amino-5-bromo-2-hydroxypyrimidine
5-bromocytosine
5-bromocytosine, 99%
6-amino-5-bromo-1h-pyrimidin-2-one
2240-25-7
CHEMBL184965
AKOS002271032
A4811
6-amino-5-bromopyrimidin-2(1h)-one
AKOS006230648
4-amino-5-bromopyrimidin-2(1h)-one
2737msz714 ,
einecs 218-806-8
unii-2737msz714
2(1h)-pyrimidinone, 4-amino-5-bromo-
FT-0600915
4-amino-5-bromo-2-pyrimidinol
2(1h)-pyrimidinone,6-amino-5-bromo-
AKOS015896909
F3096-1966
cytosine, 5-bromo-
2(1h)-pyrimidinone, 6-amino-5-bromo-
S5603
SCHEMBL64109
6-amino-5-bromo-1,2-dihydropyrimidin-2-one
MB02162
Z1737940730
4-amino-5-bromo-2(1h)-pyrimidinone #
4-amino-5-bromo-1,2-dihydropyrimidin-2-one
DTXSID60176932
STL451533
mfcd00056025
4-amino-5-bromo-2(1h)-pyrimidinon
GS-6253
5-bromocytosine, purum, >=95.0% (nt)
J-505327
BBL103792
4-amino-5-bromo-1h-pyrimidin-2-one
STL557602
SY074284
2-hydroxy-4-amino-5-bromopyrimidine
CS-W015921
BCP10035
tetrahydrofuran-2-carbaldehyde?
AMY234
CCG-266497
mfcd00038018
Q27254159
EN300-154056
PD087994
B3170
HY-W015205

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Cy and 3-Br-cy produced dual dose-response curves (DRC) at both halpha4beta2- and halpha4beta4-nACh receptors, but ACh produced dual DRC only at halpha4beta2-nACh receptors."( Activity of cytisine and its brominated isosteres on recombinant human alpha7, alpha4beta2 and alpha4beta4 nicotinic acetylcholine receptors.
Bermudez, I; Cassels, BK; Guerra, DL; Houlihan, LM; Kuo, YP; Lukas, RJ; Peng, JH; Slater, Y, 2001
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Xanthine dehydrogenase/oxidaseBos taurus (cattle)Km32.50001.80002.78003.7000AID239736; AID363291
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (1)

Processvia Protein(s)Taxonomy
xanthine catabolic processXanthine dehydrogenase/oxidaseBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (9)

Processvia Protein(s)Taxonomy
xanthine dehydrogenase activityXanthine dehydrogenase/oxidaseBos taurus (cattle)
xanthine oxidase activityXanthine dehydrogenase/oxidaseBos taurus (cattle)
iron ion bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
molybdenum ion bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
protein homodimerization activityXanthine dehydrogenase/oxidaseBos taurus (cattle)
molybdopterin cofactor bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
flavin adenine dinucleotide bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
2 iron, 2 sulfur cluster bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
FAD bindingXanthine dehydrogenase/oxidaseBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
extracellular spaceXanthine dehydrogenase/oxidaseBos taurus (cattle)
peroxisomeXanthine dehydrogenase/oxidaseBos taurus (cattle)
xanthine dehydrogenase complexXanthine dehydrogenase/oxidaseBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID363291Activity of bovine xanthine oxidase2008European journal of medicinal chemistry, Jun, Volume: 43, Issue:6
Xanthine oxidase-activated prodrugs of thymidine phosphorylase inhibitors.
AID363297Inhibition of Escherichia coli thymidine phosphorylase at 68.4 to 136.9 uM2008European journal of medicinal chemistry, Jun, Volume: 43, Issue:6
Xanthine oxidase-activated prodrugs of thymidine phosphorylase inhibitors.
AID242905Maximum binding velocity for bovine Xanthine oxidase2004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Synthesis and enzymatic evaluation of xanthine oxidase-activated prodrugs based on inhibitors of thymidine phosphorylase.
AID241954Inhibition of Thymidine phosphorylase from Escherichia coli; no inhibition at 137 uM2004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Synthesis and enzymatic evaluation of xanthine oxidase-activated prodrugs based on inhibitors of thymidine phosphorylase.
AID239736Michaelis-Menten Constant for bovine Xanthine oxidase2004Bioorganic & medicinal chemistry letters, Nov-01, Volume: 14, Issue:21
Synthesis and enzymatic evaluation of xanthine oxidase-activated prodrugs based on inhibitors of thymidine phosphorylase.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (31.58)18.2507
2000's8 (42.11)29.6817
2010's2 (10.53)24.3611
2020's3 (15.79)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.53

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.53 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.62 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.53)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]